Patents by Inventor Laurence Lins

Laurence Lins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AIML TO MONITOR CLINICAL PROTOCOL DEVIATIONS
    Publication number: 20230127903
    Abstract: A method includes patient data from a centralized database to identify protocol deviations from the patient data. Natural language processing or machine-learning is performed by a cloud computing server to perform content extraction on the protocol deviations, wherein the content extraction is performed to extract keywords, phrases, and supervised text, wherein the extracted keywords, phrases, and supervised text are used to group the protocol deviations by content. The method also includes reporting, to a user interface, multiple statistical summaries of the protocol deviations, wherein the multiple statistical summaries include a patient, site, study, and country.
    Type: Application
    Filed: October 27, 2021
    Publication date: April 27, 2023
    Inventors: Hao Ran Laurence Lin, Jonas Renstroem
  • Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
    Patent number: 8324161
    Abstract: Leukotriene B4 binding polypeptide is obtained from Ixodes ricinus. Leukotriene B4 polypeptide, the polynucleotide encoding Leukotriene B4 polypeptide, and Leukotriene B4 polypeptide related polypeptides may be used as research reagents and for treatments and diagnostics specific to animal and human diseases.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: December 4, 2012
    Assignees: Universite Libre de Bruxelles, Faculte Universitaire des Sciences Agronomiques de Gembloux
    Inventors: Edmond Godfroid, Jérôme Beaufays, Luc Vanhamme, Benoît Adam, Laurence Lins, Sébastien Santini, Robert Brasseur
  • LEUKOTRIENE B4 BINDING SOLUBLE LIPOCALIN RECEPTOR FROM IXODES RICINUS
    Publication number: 20110033469
    Abstract: Leukotriene B4 binding polypeptide is obtained from Ixodes ricinus, the polynucleotide and related polypeptides may be used as research reagents and materials for the development of treatments and diagnostics tools specific to animal and human diseases.
    Type: Application
    Filed: September 10, 2008
    Publication date: February 10, 2011
    Applicant: Faculte Universitaire des Scineces Agronomiques de Gembloux
    Inventors: Edmond Godfroid, Jérôme Beaufays, Luc Vanhamme, Benoît Adam, Laurence Lins, Sébastien Santini, Robert Brasseur
  • Antiangiogenic peptides
    Patent number: 7655626
    Abstract: The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: February 2, 2010
    Assignees: Universite de Liege, Faculte Universitaire des Sciences Agronomiques de Gembloux
    Inventors: Joseph Martial, Ingrid Struman, Ngoc-Quynh-Nhu Nguyen, Robert Brasseur, Laurence Lins
  • Antiangiogenic Peptides
    Publication number: 20080039384
    Abstract: The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp
    Type: Application
    Filed: August 11, 2005
    Publication date: February 14, 2008
    Applicant: UNIVERSITE DE LIEGE
    Inventors: Joseph Martial, Ingrid Struman, Ngoc-Quynh-Nhu Nguyen, Robert Brasseur, Laurence Lins